Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 10/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 10/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23560007 | 0.89 | SIGMAR1 (0.44) | CARM1PRMT6PRMT1PRMT8CHRM4 | |
| SCHEMBL25691521 | 0.84 | PIK3CD (0.43) | CHRM4PIK3CDCYP2D6HRH3 | |
| SCHEMBL22848538 | 0.84 | CHRM4 (0.38) | CARM1PRMT6CHRM4PIK3CDSIGMAR1 | |
| SCHEMBL25469081 | 0.82 | PRMT6 (0.40) | CARM1PRMT6CHRM4PIK3CDCYP2D6 | |
| SCHEMBL23945990 | 0.82 | CHRM4 (0.37) | CARM1PRMT6CHRM4PIK3CDCYP2D6 | |
| SCHEMBL23695861 | 0.81 | PIK3CD (0.42) | CARM1PRMT6PRMT1PRMT8PIK3CD | |
| SCHEMBL23568463 | 0.81 | L3MBTL1 (0.44) | CARM1PRMT6PRMT1PRMT8PIK3CD | |
| SCHEMBL23567925 | 0.81 | CHRM4 (0.36) | CARM1PRMT6CHRM4PIK3CDCYP2D6 | |
| SCHEMBL25883845 | 0.81 | CHRM4 (0.36) | CARM1PRMT6CHRM4PIK3CDCYP2D6 | |
| SCHEMBL24673663 | 0.80 | CHRM4 (0.36) | CARM1PRMT6CHRM4PIK3CDCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021127190-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CARM1 824/4885PRMT6 1616/4885PRMT1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.